New Antimicrobial Development Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for New Antimicrobial Development. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
New Antimicrobial Development Indian Medical PG Question 1: Antimicrobial combinations are used in all except
- A. Intra abdominal infections
- B. Malaria
- C. Tuberculosis
- D. Gonorrhea (Correct Answer)
New Antimicrobial Development Explanation: ***Gonorrhea***
- While **gonorrhea** treatment has evolved to include **dual therapy** (e.g., ceftriaxone + azithromycin), this is primarily for co-treatment of potential Chlamydia co-infection and to combat emerging resistance, given as a **single-session treatment**.
- Unlike the other conditions, gonorrhea does not require a **prolonged multi-drug regimen** with true synergy or prevention of resistance development during treatment.
- The combination is more about empiric co-coverage and resistance concerns rather than the classic indications for antimicrobial combinations (synergy, preventing resistance emergence during therapy, polymicrobial coverage).
- This distinguishes it from conditions requiring extended combination therapy.
*Intra-abdominal infections*
- Involve **polymicrobial etiology** requiring combination therapy to cover both aerobic (e.g., Enterobacteriaceae) and anaerobic bacteria (e.g., Bacteroides fragilis).
- Combination therapy ensures broad-spectrum coverage for mixed infections and prevents treatment failures in complex intra-abdominal sepsis.
*Malaria*
- **Artemisinin-based combination therapies (ACTs)** are the standard first-line treatment for uncomplicated *Plasmodium falciparum* malaria.
- Combination therapy reduces drug resistance risk and improves cure rates by targeting different mechanisms of action against the parasite.
*Tuberculosis*
- Treatment always involves **multi-drug regimen** (isoniazid, rifampicin, pyrazinamide, ethambutol) to prevent emergence of drug-resistant strains.
- Multi-drug therapy is essential because *Mycobacterium tuberculosis* rapidly develops resistance if exposed to single agents during the prolonged treatment course.
New Antimicrobial Development Indian Medical PG Question 2: Which class of antibiotics is primarily inactivated by extended-spectrum β-lactamases (ESBLs)?
- A. Macrolides
- B. Quinolones
- C. Aminoglycosides
- D. Third-generation cephalosporins (Correct Answer)
New Antimicrobial Development Explanation: ***Third-generation cephalosporins***
- **ESBLs** are a group of enzymes primarily known for their ability to hydrolyze and inactivate **third-generation cephalosporins** (e.g., ceftriaxone, ceftazidime) and other beta-lactam antibiotics.
- This inactivation mechanism renders agents like **ceftriaxone ineffective** against bacteria producing these enzymes, leading to significant treatment challenges.
*Macrolides*
- **Macrolides** (e.g., azithromycin, erythromycin) act by **inhibiting bacterial protein synthesis** through binding to the 50S ribosomal subunit.
- Their mechanism of action is distinct from beta-lactam antibiotics, and they are generally **not inactivated by ESBL enzymes**.
*Quinolones*
- **Quinolones** (e.g., ciprofloxacin, levofloxacin) primarily function by **inhibiting bacterial DNA gyrase and topoisomerase IV**, thereby preventing DNA replication.
- **ESBLs do not target quinolones**; resistance to quinolones typically arises from mutations in gyrase or efflux pump mechanisms.
*Aminoglycosides*
- **Aminoglycosides** (e.g., gentamicin, amikacin) are bactericidal antibiotics that **bind to the 30S ribosomal subunit**, interfering with protein synthesis.
- While resistance to aminoglycosides can occur through modifying enzymes, **ESBLs do not inactivate this class of antibiotics**.
New Antimicrobial Development Indian Medical PG Question 3: Which of the following drugs does not inhibit bacterial protein synthesis?
- A. Aminoglycosides
- B. Chloramphenicol
- C. Clindamycin
- D. Sulfonamides (Correct Answer)
New Antimicrobial Development Explanation: ***Sulfonamides***
- Sulfonamides do **NOT** inhibit bacterial protein synthesis; instead, they inhibit **folic acid synthesis**.
- They act as **competitive inhibitors** of dihydropteroate synthase, an enzyme involved in the synthesis of dihydrofolic acid.
- Folic acid is essential for nucleotide synthesis and DNA replication, making sulfonamides bacteriostatic agents that work through a completely different mechanism than protein synthesis inhibitors.
*Aminoglycosides*
- Aminoglycosides bind to the **30S ribosomal subunit**, causing misreading of mRNA and premature termination of protein synthesis.
- This leads to the production of **abnormal and non-functional proteins**, ultimately killing the bacterial cell.
*Chloramphenicol*
- Chloramphenicol binds to the **50S ribosomal subunit**, thereby inhibiting the peptidyl transferase enzyme.
- This prevents the formation of **peptide bonds** between amino acids, effectively blocking protein elongation.
*Clindamycin*
- Clindamycin also binds to the **50S ribosomal subunit**, specifically at the P-site.
- It interferes with the **translocation step** of protein synthesis, preventing ribosomal movement along the mRNA.
New Antimicrobial Development Indian Medical PG Question 4: Targeted critical agents used in a bioterrorist event are except?
- A. Ricinus communis
- B. Small pox
- C. Coxiella burnetii (Correct Answer)
- D. Viral hemorrhagic fevers -Junin virus
New Antimicrobial Development Explanation: ***Coxiella burnetii***
- This is the **correct answer** as it is classified as a **Category B biological agent**, not a Category A critical agent.
- While *C. burnetii* causes **Q fever** and has high infectivity with potential for widespread illness, it typically has **lower mortality rates** compared to Category A agents.
- Category B agents are second-priority because they are moderately easy to disseminate but cause lower mortality than Category A agents.
*Ricinus communis*
- This refers to **ricin toxin** derived from castor beans, classified as a **Category B agent**.
- However, ricin is considered more dangerous than Q fever due to its potent toxicity and lack of antidote.
- Can cause severe multi-organ damage upon inhalation or ingestion, though less lethal than Category A agents.
*Smallpox*
- Caused by **variola virus**, classified as a **Category A critical agent**.
- High infectivity, severe illness, high mortality rate, and lack of natural immunity in most populations.
- Historical use as a bioweapon and potential for rapid global spread make it a top-tier threat.
*Viral hemorrhagic fevers - Junin virus*
- **Category A critical agent** due to high infectivity, severe disease presentation, and high mortality rates.
- Includes agents like Ebola, Marburg, Lassa, and Junin viruses that cause severe multi-system disease.
- Person-to-person transmission potential and lack of effective treatments make these priority threats.
New Antimicrobial Development Indian Medical PG Question 5: Which is the fastest microbicidal agent against M. leprae?
- A. Minocycline
- B. Clofazimine
- C. Rifampicin (Correct Answer)
- D. Dapsone
New Antimicrobial Development Explanation: ***Rifampicin***
- **Rifampicin** is widely recognized as the most rapidly acting bactericidal drug against **Mycobacterium leprae**, leading to rapid clearance of bacilli.
- Its potent and fast action is crucial for reducing the bacterial burden quickly and preventing further transmission of **leprosy**.
*Minocycline*
- **Minocycline** is an effective anti-leprosy drug, but it is **bacteriostatic** rather than rapidly bactericidal compared to rifampicin.
- It is often used as an alternative in cases of **drug resistance** or intolerance to first-line agents but is not the fastest acting.
*Clofazimine*
- **Clofazimine** is an anti-leprosy drug with **bacteriostatic** and anti-inflammatory properties, but its action is slower than rifampicin.
- It is valuable in multi-drug therapy for preventing resistance and managing **lepromatous leprosy**, but not for rapid killing.
*Dapsone*
- **Dapsone** is a foundational anti-leprosy drug, but its action against **M. leprae** is generally considered **bacteriostatic** and slow.
- While essential for long-term treatment, it does not achieve the rapid sterilizing effect seen with rifampicin.
New Antimicrobial Development Indian Medical PG Question 6: The bacterial drug resistance in tuberculosis results from which mechanism?
- A. Transduction
- B. Transformation
- C. Plasmid mediated resistance
- D. Mutation (Correct Answer)
New Antimicrobial Development Explanation: **Explanation:**
The development of drug resistance in *Mycobacterium tuberculosis* (MTB) is unique compared to many other bacteria.
**Why Mutation is Correct:**
In *Mycobacterium tuberculosis*, antimicrobial resistance occurs exclusively due to **spontaneous chromosomal mutations**. Unlike many Gram-negative or Gram-positive bacteria, MTB does not possess horizontal gene transfer mechanisms like plasmids or transposons. These random genetic mutations occur at a predictable frequency (e.g., 1 in $10^6$ to $10^8$ cell divisions). When a patient is treated with inadequate monotherapy or irregular dosing, these resistant mutants are "selected" and survive to multiply, leading to **acquired resistance**.
**Why Incorrect Options are Wrong:**
* **Transduction & Transformation (A & B):** These are forms of horizontal gene transfer involving bacteriophages and the uptake of free DNA, respectively. While common in bacteria like *Staphylococcus* or *Streptococcus*, they have no documented role in clinical drug resistance in MTB.
* **Plasmid-mediated resistance (C):** Plasmids are extrachromosomal DNA elements frequently responsible for multi-drug resistance in Enterobacteriaceae (e.g., via R-plasmids). *M. tuberculosis* does not harbor resistance-carrying plasmids.
**High-Yield Clinical Pearls for NEET-PG:**
* **Multi-Drug Resistant TB (MDR-TB):** Defined as resistance to at least **Isoniazid (H)** and **Rifampicin (R)**.
* **Genetic Targets:**
* **Rifampicin resistance:** Mutation in the **rpoB** gene (beta subunit of RNA polymerase).
* **Isoniazid resistance:** Mutation in **katG** (most common) or **inhA** genes.
* **DOTS Strategy:** The primary reason for using "Multi-Drug Therapy" in TB is to prevent the selection of these spontaneous resistant mutants. The probability of a bacilli developing simultaneous mutations to two drugs is mathematically negligible ($10^{-6} \times 10^{-8} = 10^{-14}$).
New Antimicrobial Development Indian Medical PG Question 7: How does Staphylococcus aureus become resistant to methicillin?
- A. Heat shock protein
- B. Protein A
- C. Transpeptidase (Correct Answer)
- D. Protein C
New Antimicrobial Development Explanation: ### Explanation
**1. Why Transpeptidase is Correct:**
Methicillin resistance in *Staphylococcus aureus* (MRSA) is primarily mediated by the acquisition of the **mecA gene**. This gene encodes a modified **Penicillin-Binding Protein (PBP2a)**. PBPs are essentially **transpeptidases**, enzymes responsible for cross-linking the peptidoglycan layers of the bacterial cell wall.
While standard PBPs are inhibited by beta-lactam antibiotics (like methicillin or oxacillin), the modified transpeptidase (PBP2a) has a **low affinity** for these drugs. This allows the bacteria to continue cell wall synthesis even in the presence of the antibiotic, leading to resistance.
**2. Why Other Options are Incorrect:**
* **Option A (Heat shock protein):** These are molecular chaperones that help in protein folding and stress response; they do not mediate antibiotic resistance in Staphylococci.
* **Option B (Protein A):** This is a key virulence factor of *S. aureus* that binds to the **Fc portion of IgG**, preventing opsonization and phagocytosis. It is not involved in drug resistance.
* **Option C (Protein C):** This is a host (human) anticoagulant protein that inactivates Factors Va and VIIIa. It has no role in bacterial physiology.
**3. High-Yield Clinical Pearls for NEET-PG:**
* **Gold Standard Test:** The detection of the **mecA gene** by PCR is the gold standard for identifying MRSA.
* **Phenotypic Screening:** Cefoxitin disk diffusion is preferred over methicillin/oxacillin disks for screening MRSA in labs because it is a better inducer of the mecA gene.
* **Drug of Choice:** **Vancomycin** is the traditional drug of choice for MRSA. For VRSA (Vancomycin-resistant), Linezolid or Daptomycin are used.
* **Exceptions:** MRSA is resistant to all beta-lactams **except** 5th generation cephalosporins (e.g., **Ceftaroline**).
New Antimicrobial Development Indian Medical PG Question 8: Which of the following is NOT a mechanism of resistance to MRSA?
- A. Resistance is chromosomally mediated.
- B. Produced mainly by alteration in PBPs.
- C. MRSA resistance is absolutely beta-lactamase dependent. (Correct Answer)
- D. Intrinsic resistance is known.
New Antimicrobial Development Explanation: **Explanation:**
**Why Option C is the correct answer:**
The hallmark of Methicillin-resistant *Staphylococcus aureus* (MRSA) is that its resistance is **independent** of beta-lactamase production. While many Staphylococci produce penicillinase (a beta-lactamase), MRSA resistance specifically arises from the acquisition of the **mecA gene**. This gene encodes an altered Penicillin-Binding Protein (**PBP2a**), which has a very low affinity for almost all beta-lactam antibiotics (penicillins, cephalosporins, and carbapenems). Therefore, even if a drug is "beta-lactamase stable" (like Methicillin or Nafcillin), it cannot bind to PBP2a, rendering the drug ineffective.
**Analysis of incorrect options:**
* **Option A (Chromosomally mediated):** This is a true statement. The *mecA* gene is located on a mobile genetic element called the **Staphylococcal Cassette Chromosome (SCCmec)**, which integrates into the bacterial chromosome.
* **Option B (Alteration in PBPs):** This is the primary mechanism. The production of **PBP2a** instead of the normal PBPs prevents the antibiotic from inhibiting cell wall synthesis.
* **Option D (Intrinsic resistance):** This is true. MRSA resistance is considered "intrinsic" because it is a structural change in the target site (PBP) that applies to the entire class of beta-lactams, regardless of the presence of enzymes.
**High-Yield Clinical Pearls for NEET-PG:**
* **Drug of Choice for MRSA:** Vancomycin (Glycopeptide).
* **Exception:** 5th generation cephalosporins (**Ceftaroline** and Ceftobiprole) are the only beta-lactams active against MRSA because they can bind to PBP2a.
* **Detection:** Cefoxitin disk diffusion test is the preferred method in labs to detect MRSA (it is a better inducer of the *mecA* gene than methicillin).
* **BORSA:** "Borderline Oxacillin-Resistant *S. aureus*" refers to strains that are resistant due to *hyper-production* of beta-lactamase, not the *mecA* gene.
New Antimicrobial Development Indian Medical PG Question 9: Hain test is used for:
- A. Detection of INH resistance only
- B. Detection of rifampicin resistance only
- C. Detection of both rifampicin and INH resistance (Correct Answer)
- D. Detection of resistance to all first-line anti-tuberculosis drugs
New Antimicrobial Development Explanation: **Explanation:**
The **Hain test**, also known as the **GenoType MTBDRplus** assay, is a commercial Line Probe Assay (LPA) used for the rapid molecular detection of drug resistance in *Mycobacterium tuberculosis*.
**1. Why Option C is Correct:**
The Hain test utilizes PCR and reverse hybridization to identify specific mutations in the MTB genome. It simultaneously targets:
* **rpoB gene:** Mutations here confer resistance to **Rifampicin**.
* **katG and inhA promoter genes:** Mutations here confer resistance to **Isoniazid (INH)**.
Because it detects resistance to both primary bactericidal drugs, it is the gold standard for the rapid diagnosis of Multidrug-Resistant TB (MDR-TB).
**2. Why Other Options are Incorrect:**
* **Options A & B:** These are incomplete. While the test does detect resistance to these drugs individually, its clinical utility lies in its ability to screen for both simultaneously to identify MDR-TB.
* **Option D:** The Hain test (MTBDRplus) only covers Rifampicin and INH. Resistance to other first-line drugs (Pyrazinamide, Ethambutol) or second-line drugs (Fluoroquinolones, Aminoglycosides) requires different assays, such as the **MTBDRsl** (Second Line) test.
**High-Yield Clinical Pearls for NEET-PG:**
* **Turnaround Time:** Provides results within 24–48 hours, much faster than culture-based DST.
* **Prerequisite:** It can be performed on smear-positive sputum samples or culture isolates.
* **Key Genes to Remember:**
* *rpoB* = Rifampicin
* *katG* (high-level) & *inhA* (low-level) = INH.
* **NTEP Protocol:** In India, LPA is a key component of the Programmatic Management of Drug-Resistant TB (PMDT).
New Antimicrobial Development Indian Medical PG Question 10: Which of the following drugs should not be used to treat Klebsiella infection?
- A. Ampicillin (Correct Answer)
- B. Amikacin
- C. Imipenem
- D. Tigecycline
New Antimicrobial Development Explanation: ### Explanation
The correct answer is **Ampicillin**.
**1. Why Ampicillin is the correct answer:**
*Klebsiella pneumoniae* possesses a **constitutive (intrinsic) resistance** to Ampicillin and Amoxicillin. This is due to the presence of chromosomally mediated **SHV-1 beta-lactamase** enzymes that hydrolyze these penicillins. Therefore, Ampicillin is clinically ineffective against *Klebsiella* species regardless of the strain's sensitivity profile in the lab.
**2. Analysis of Incorrect Options:**
* **B. Amikacin:** This is an Aminoglycoside often used as part of a combination therapy for serious Gram-negative infections, including *Klebsiella*.
* **C. Imipenem:** A Carbapenem that remains one of the most potent drugs against *Klebsiella*, particularly for Extended-Spectrum Beta-Lactamase (ESBL) producing strains. However, resistance is rising due to Carbapenemases (KPC).
* **D. Tigecycline:** A Glycylcycline used as a "reserve drug" for Multi-Drug Resistant (MDR) *Klebsiella*, including Carbapenem-Resistant Enterobacteriaceae (CRE).
**3. High-Yield Clinical Pearls for NEET-PG:**
* **Intrinsic Resistance:** Always remember that *Klebsiella* is naturally resistant to Ampicillin. Similarly, *Proteus mirabilis* is intrinsically resistant to Nitrofurantoin, and *Pseudomonas* is resistant to many common antibiotics like Tigecycline.
* **ESBL Production:** *Klebsiella* is a frequent producer of ESBLs, which confer resistance to 3rd generation Cephalosporins (Ceftriaxone, Ceftazidime). The drug of choice for ESBL-producing *Klebsiella* is a **Carbapenem**.
* **Morphology:** On MacConkey agar, *Klebsiella* produces large, mucoid, pink colonies (Lactose Fermenter) due to its prominent polysaccharide capsule.
More New Antimicrobial Development Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
